Boston Scientific in July 2021 exercised its option to acquire the remaining shares of PFA tech developer Farapulse. [Image courtesy of Boston Scientific]
Pulsed-field ablation (PFA) — a non-thermal method for cardiac ablation — has the potential to positively disrupt the atrial fibrillation market.
Amid the excitement around the technology, Medtronic announced in January that it would acquire cardiac mapping and ablation technology developer Affera for nearly $1 billion. Meanwhile, Boston Scientific in February closed its $1.75 billion acquisition of Baylis Medical — the creator of advanced transseptal puncture platforms to enhance safety, efficacy and efficiency when crossing the atrial septum to deliver therapies in the left side of the heart. Months before, Boston Scientific exercised its option to acquire the remaining shares of PFA tech developer Farapulse.
Come to DeviceTalks Boston — May 10-11, 2022 — and hear from leaders at Boston Scientific, Medtronic and Acutus Medical about what the new technology means for innovation and for atrial fibrillation patients. (Register today!)
Panelists include:
- Dr. Kenneth Stein, SVP & CMO, Boston Scientific;
- Dr. Khaldoun Tarakji, VP Medical Affairs and CMO of Cardiac Ablation Solutions, Medtronic;
- Dr. Steven Mickelsen Chief Translational Science Officer, Acutus Medical.
Questions from the audience will be encouraged in this wide-ranging discussion.